NCT04671056View on ClinicalTrials.gov

Drug Interaction Study of MGL-3196 With Pioglitazone

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

November 9, 2018

Primary Completion Date

December 11, 2018

Study Completion Date

January 5, 2019

Conditions
Healthy
Interventions
DRUG

MGL-3196

MGL-3196 100 mg tablet administered orally in the morning for 13 days

DRUG

Pioglitazone 15mg

Pioglitazone 15 mg tablet administered orally on 2 separate days, initially on one day alone and again after MGL-3196 has been dosed to steady-state

Trial Locations (1)

68502

Celerion, Lincoln

Sponsors
All Listed Sponsors
lead

Madrigal Pharmaceuticals, Inc.

INDUSTRY

NCT04671056 - Drug Interaction Study of MGL-3196 With Pioglitazone | Biotech Hunter | Biotech Hunter